Comment by djierardi
8 hours ago
In medicine, or drug discovery more generally, there's FAR too little empirical data for training of ML generally. See OpenAdmet. The kickback to "oh but yeah cancer" is currently just hype. DeepMind has pivoted to this realm but has no demonstrable improvements. For the typical phase 1-2-3 pipeline of drugs, stretching many years, there's not yet any demonstrable improvements.
I think your perspective is limited- in cancer, we have copious genomic information that informs treatment (including clinical trials where treatment is determined by AI).